$97.5 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 105.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SCLN | Sell | SCICLONE PHARMACEUTICALS INC | $14,138,000 | -37.3% | 1,082,532 | -47.2% | 14.50% | -45.5% |
| New | Viveve Medical, Inc | $10,659,000 | – | 2,599,711 | +100.0% | 10.93% | – | |
| New | Aegerion Pharmaceuticals, Inc. (NOTES)note | $9,861,000 | – | 17,300,000 | +100.0% | 10.11% | – | |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $9,081,000 | -47.5% | 811,563 | -60.8% | 9.31% | -54.3% |
| TBRA | Sell | TOBIRA THERAPEUTICS INC | $8,008,000 | +17.5% | 637,567 | -23.5% | 8.21% | +2.2% |
| PTIE | Sell | PAIN THERAPEUTICS INC | $6,215,000 | -21.1% | 2,837,878 | -19.6% | 6.37% | -31.4% |
| QLTI | New | QLT Inc. | $5,367,000 | – | 3,779,274 | +100.0% | 5.50% | – |
| SGNT | Buy | SAGENT PHARMACEUTICALS INC | $5,337,000 | +31.7% | 356,307 | +7.0% | 5.47% | +14.5% |
| VCEL | Buy | VERICEL CORP | $5,063,000 | -39.1% | 2,250,000 | +58.7% | 5.19% | -47.0% |
| CUTR | Buy | CUTERA INC | $4,910,000 | +17.2% | 438,000 | +17.6% | 5.03% | +1.9% |
| REPH | Buy | RECRO PHARMA INC | $3,408,000 | +141.0% | 428,670 | +81.0% | 3.49% | +109.5% |
| ALR | New | Alere Inc. | $3,126,000 | – | 75,000 | +100.0% | 3.20% | – |
| SCMP | Buy | Sucampo Pharmaceuticals, Inc. | $2,346,000 | +4015.8% | 213,860 | +3990.7% | 2.40% | +3489.6% |
| PCRX | New | Pacira Pharmaceuticals, Inc. | $1,759,000 | – | 52,157 | +100.0% | 1.80% | – |
| New | PERNIX THERAPEUTICS HOLDINGSnote | $1,380,000 | – | 6,000,000 | +100.0% | 1.42% | – | |
| FLML | New | Flamel Technologies SA | $1,375,000 | – | 128,005 | +100.0% | 1.41% | – |
| BSTC | Buy | BioSpecifics Technologies Corp. | $1,198,000 | +34.2% | 30,000 | +17.0% | 1.23% | +16.6% |
| New | Enanta Pharmaceuticals, Inc. | $1,160,000 | – | 52,616 | +100.0% | 1.19% | – | |
| DSCI | Sell | DERMA SCIENCES INC | $1,116,000 | -29.1% | 283,306 | -44.2% | 1.14% | -38.4% |
| VCYT | New | Veracyte, Inc. | $940,000 | – | 186,926 | +100.0% | 0.96% | – |
| CPIX | New | Cumberland Pharmaceuticals, Inc. | $580,000 | – | 128,798 | +100.0% | 0.60% | – |
| AVIR | New | Aviragen Therapeutics, Inc. | $412,000 | – | 294,269 | +100.0% | 0.42% | – |
| DRRX | New | DURECT Corporation | $98,000 | – | 80,160 | +100.0% | 0.10% | – |
| BDSI | Exit | BioDelivery Sciences International, Inc. | $0 | – | -8,523 | -100.0% | -0.03% | – |
| INSYQ | Exit | INSYS Therapeutics, Inc. | $0 | – | -2,000 | -100.0% | -0.04% | – |
| ANIP | Exit | ANI Pharmaceuticals, Inc. | $0 | – | -1,650 | -100.0% | -0.07% | – |
| RPTP | Exit | Raptor Pharmaceuticals Corp. | $0 | – | -20,000 | -100.0% | -0.11% | – |
| ZLTQ | Exit | ZELTIQ Aesthetics, Inc. | $0 | – | -70,000 | -100.0% | -2.24% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -3,743,340 | -100.0% | -2.35% | – |
| Exit | PERNIX THERAPEUTICS HOLDINGSdebt | $0 | – | -6,000,000 | -100.0% | -2.73% | – | |
| PTX | Exit | PERNIX THERAPEUTICS HOLDINGS | $0 | – | -3,215,861 | -100.0% | -3.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.